S100B and metastatic melanoma: In retrospective studies performed among metastatic melanoma patients treated with anti-PD-1, anti-CTLA-4 or anti-CTLA-4+anti-PD-1 the baseline serum S100B level proved to be independent predictor of primary resistance to therapy and overall survival (46, 48, 55).